Find a Clinical Trial

Showing 11 - 20 of 225 Trials

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative

Principal Investigator:

Julia E McGuinness, MD

Contact Number:

212-342-5162

NCT Number:

NCT05232916

Population:

Adult

Phase:

III

The purpose of this research is to test how well an investigational study drug (medication), GLSI-100, can prevent your cancer from coming back. The research study will also collect information about the safety of the medication. The research will also study how the medication works and who responds the best to the medication. GLSI-100 is a combination of a study medication called GP2 and the FDA-approved medication, granulocyte-macrophage colony-stimulating factor (GM-CSF) or sargramostim (Leukine®). It is thought that this medication will work by helping your immune system identify and...
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast

Principal Investigator:

Meghna S Trivedi, MD

Contact Number:

212-342-5162

NCT Number:

NCT05382286

Population:

Adult

Phase:

III

The purpose of this study is to see if sacituzumab govitecan in combination with pembrolizumab can improve lifespans of patients with with advanced triple- negative breast cancer (TNBC) and their tumor does not grow or spread when compared to chemotherapy (paclitaxel, or nab-paclitaxel, or the combination of gemcitabine and carboplatin), a commonly used treatment for previously untreated advanced TNBC. The combination of sacituzumab govitecan and pembrolizumab has not been approved by any health authorities for previously untreated advanced TNBC. Information on the side effects, study...
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1

Principal Investigator:

Meghna S Trivedi, MD

Contact Number:

212-342-5162

NCT Number:

NCT05382299

Population:

Adult

Phase:

III

The purpose of this study is to see if sacituzumab govitecan can improve lifespans of patients with advanced triple-negative breast cancer (TNBC) and their tumor does not grow or spread when compared to chemotherapy (paclitaxel, or nab-paclitaxel, or the combination of gemcitabine and carboplatin), a commonly used treatment for previously untreated advanced TNBC. Information on the side effects, treatment benefit, your quality of life, and other supporting data will also be collected in this study. This is a randomized open-label study which means the study treatment you take will be chosen...
A Phase III, Randomised, Open-Label Study of Savolitinib inCombination With Osimertinib Versus Platinum-Based DoubletChemotherapy in Participants With EGFR MutatedMET-Overexpressed and/or Amplified, Locally Advanced orMetastatic Non-Small Cell Lung Cancer

Principal Investigator:

Catherine Ann Shu, MD

Contact Number:

212-342-5162

NCT Number:

NCT05261399

Population:

Adult

Phase:

III

The purpose of this study is to learn more about an investigational drug called savolitinib in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC) compared to platinum-based doublet chemotherapy (a standard of care treatment). Participants will be randomly assigned to one of two study groups at the beginning of this study. This means participants will be assigned to a study group by chance, like flipping a coin or rolling dice. Investigational means that the drug is not approved by any health authority, except for use in research studies like this. People who...
An Adaptive Phase 3, Randomized, Open-Label,Multicenter Study to Compare the Efficacy and Safety ofAxicabtagene Ciloleucel versus Standard of Care Therapy asFirst-Line Therapy in Subjects with High-Risk Large B-CellLymphoma (ZUMA-23)

Principal Investigator:

Ran Reshef, MD, MSc

Contact Number:

212-342-5162

NCT Number:

NCT05605899

Population:

Adult

Phase:

III

The purpose of this study is to find out if the experimental product, axi-cel, is safe and effective in treating your lymphoma, compared to standard of care (SOC) therapy (chemotherapy), which includes either R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone) or DA EPOCH R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab). The experimental treatment would involve removing some of your immune cells, genetically engineering those cells to identify cancer, receiving additional therapy while you wait for those cells to...
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMABVERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING INPATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA

Principal Investigator:

Benjamin Izar, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT05608291

Population:

Adult

Phase:

III

The purpose of this study is to see if the combination of fianlimab (REGN3767) and cemiplimab (REGN2810) is an effective treatment compared to pembrolizumab in participants that have had melanoma removal surgery but are still at high risk for the return of the disease. This study involves 2 study drugs: fianlimab (REGN3767) and cemiplimab (REGN2810). The study drug, fianlimab is not approved by Food and Drug Administration (FDA). The study drug, cemiplimab, is approved in the FDA for the treatment of advanced cancers but it is considered investigational in this study because it has not been...
A Phase 3, Open-Label, Randomized, Multi-Center Study ofDZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon

Principal Investigator:

Catherine Ann Shu, MD

Contact Number:

212-342-5162

NCT Number:

NCT05668988

Population:

Adult

Phase:

III

The purpose of this study is to see how safe the study drug, DZD9008, is, how it works, and assess the efficacy of the study drug verse standard treatment of your disease. DZD9008 is an investigational drug that has not been approved by United States Food and Drug Administration (FDA), for the treatment of NSCLC. Pemetrexed combined with Carboplatin is the standard treatment for advanced non-small cell lung cancer (NSCLC) with Exon 20 Insertion Mutation. The EGFR (epidermal growth factor receptor) is a gene that regulates cell growth and this gene can change, or mutate, in some people with...
A Phase III, Double-blind, Randomised, Placebo-Controlled,International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete

Principal Investigator:

Catherine Ann Shu, MD

Contact Number:

212-342-5162

NCT Number:

NCT05120349

Population:

Adult

Phase:

III

The purpose of this study to learn more about whether the study drug osimertinib (TAGRISSOTM) is more effective than placebo in participants with epidermal growth factor receptor (EGFR) mutated stage IA2 or IA3 Non-Small Cell Lung Cancer (NSCLC) after complete surgical removal of the tumor. Stages IA2 and IA3 refer to tumor size. A placebo is an inactive substance or other intervention that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or other intervention are compared to the effects of the placebo. We are also...
AGCT1532: Phase 3 Accelerated BEP Trial:A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT02582697

Population:

Pediatrics/Adult

Phase:

III

This is a study for patients between 11 years and 45 years who have newly diagnosed intermediate or poor-risk metastatic germ cell tumors (GCTs). This study is looking at whether giving treatment with Bleomycin, Etoposide, and Cisplatin (BEP)every 2 weeks (accelerated BEP) or every 3 weeks (standard BEP) is better. Participants will be randomized to either Arm A: standard BEP or Arm B: accelerated BEP. All participants will receive a medication to stimulate the body to make white blood cells which has allowed some chemotherapy regimens to be given with a shorter than usual cycle length, while...
A Prospective Randomized Study of Ramucirumab Plus Pembrolizumab Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

Principal Investigator:

Stephanie Smith-Marrone, MD

Contact Number:

212-342-5162

NCT Number:

NCT05633602

Population:

Adult

Phase:

III

The purpose of this study is to compare the drugs ramucirumab and pembrolizumab to standard of care treatment in patients whose lung cancer has progressed on immunotherapy. The study doctors hope to learn if the drug combination will help patients with stage IV or recurrent non-small cell lung cancer (NSCLC) live longer. The study is set up to find out if this drug combination is better, the same, or worse than the usual treatment. The usual approach is the care most people get for lung cancer. For patients not in a study, the usual approach is treatment with chemotherapy, which is approved...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages